SkinBioTherapeutics SBTX.L · GBp

Its shares trade on LSE under the ticker SBTX.L. It has been listed since 5 April 2017. In the fiscal year to 30 June 2025, it reported revenue of £4.6m and a net loss of £696,253. At that date it held total assets of £12.1m and shareholders' equity of £9.4m.

SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Macclesfield, Cheshire. The company went IPO on 2017-04-05. The Company’s platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company’s SkinBiotix platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. The company focuses on three specific skin healthcare sectors: cosmetics, infection control and eczema. In each of these areas, the Company plans to exemplify its technology in human studies. The Company’s program is focused on the application of the Skinbiotix platform in managing sensitive skin in the cosmetics industry. SkinBiotix increases the rate of skin healing in response to injury.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Martin HuntNon-Executive Independent Chairman of the Board£71,015
• Mr. Stuart AshmanChief Executive Officer, Executive Director, since 2019£324,642
• Mr. Simon HewitsonChief Operating Officer, Executive Director, since 2025
• Ms. Danielle BekkerNon-Executive Independent Director£26,250
• Dr. Catherine PrescottNon-Executive Independent Director£36,099

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.